*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.

Slides:

Advertisements

Similar presentations

17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.

Advertisements

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.

Foundations of Regulation

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

Electronic Common Technical Document (eCTD) Update Jon Clark ICH M2 Deputy Topic Leader January 21, 2003.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

European Standardisation: A short insight

Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.

Biopharmaceutical Regulatory Requirements 1. Marketing Authorization for Chemical Entities MoH Federal Commission for the Protection against Health Risks.

A Case Study in the Value of Harmonisation Yoshikazu HAYASHI Deputy Director Evaluation and Licensing Division Pharmaceutical & Food Safety Bureau Ministry.

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

Good Manufacturing Practices Working Group. Working Group Members USA: Molzon Justina: Coordinator ARG: Rodolfo Mochetto BRA: Suzana Machado Marcelo.

Presented by: Karen Ginsbury For IFF, Denmark March 2012.

Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.

Justina A. Molzon, MS Pharm, JD

Overview of ICH Procedures July 2015

On ICH Feb. 13, 2013 Toshi Tominaga Ph. D. Food and Drug Evaluation Center, Osaka City Univ. Hospital International Regulatory Harmonization Amid Globalization.

What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.

Good Clinical Practice GCP overview

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Date: in 12 pts The cultural dimension of the Eastern Partnership Culture Gyöngyi Mikita Policy Officer, "Culture Policy, Diversity and Intercultural Dialogue"

Bioequivalence and Bioavailability Working Group.

ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

Working together with EFSA in making Europe’s food safe Warszawa, 16. April 2013 Cooperation between EFSA and Member States Jacek Postupolski National.

DETERMINATION OF RELATED SUBSTANCES & IMPURITIES IN DRUGS BY ICH GUIDE LINES BY M.PAUL RICHARDS.

Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:

The Codex Alimentarius Commission

EUnetHTA Joint Action 2010–2012 | EUnetHTA Joint action Sharing expertise and efforts Iris Pasternack, research officer, FINOHTA.

IMPLEMENTATION STATUS OF THE CTD IN THE OTHER ICH-REGIONS: Europe, Japan and Canada Christelle Anquez Office of International Programs, OC Food and Drug.

Federal Food, Drug and Cosmetic Act (FFDCA)

Anthony Serracino Inglott Chairman of the Malta Medicines Authority

- 1 - TTA View of Budget & Secretariat Functions March 28~29, 2012 (Tokyo, Japan) TTA.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.

CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.

ICH Quality Topics Update

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

IPEC Overview The Impact of Globalisation and IPEC’s Role Janeen Skutnik Past Chair – IPEC Americas.

1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

JMAFF (Chair of Biologicals Quality Monitoring EWG)

VICH General Principles and current update of VICH Outreach Forum activity 1.

VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.

Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.

-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.

1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.

Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.

Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.

The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.

INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.

How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.

LATAM Latin America Registration Requirements and Harmonization Efforts April 2011 DIA RA SIAC AprilApril.

How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.

1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.

ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.

VICH General Principles and

Grade A Dairy Equivalence

Overview of the EAC Pharmacovigilance and Post-Marketing Surveillance Systems 1ST International High Level Multi-Stakeholder Conference Nairobi, 2-4.

The Codex Alimentarius Commission

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.

ICH-GCP Avinash Kondawar M. Pharm Lead CRA

Michelle Limoli, Pharm.D.

What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific.

Innovative Medicines Initiative:

Fundamentals of Electronic Submissions and eCTD

The Benefits of VICH to Emerging Countries

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Presentation transcript:

*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration. FDA Public Meeting The Future of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Overview of ICH: A description of the structure and harmonization process. Christelle Anquez* Office of International Programs, Office of Commissioner

I C H INTERNATIONAL CONFERENCE ON HARMONISATION of Technical Requirements for the Registration of Pharmaceuticals for Human Use

A Unique Approach Agreement between the European Union, Japan and the USA to take action on Harmonisation A joint initiative involving regulators and industry as equal partners in technical discussions

Inauguration of ICH April 1990, EFPIA Offices, Brussels First meeting of the Six Parties, and IFPMA –To plan an International Conference –To establish Terms of Reference –To establish a Method of Working

ICH Objectives Identification and elimination of the need to duplicate studies to meet different regulatory requirements. More efficient use of resources (human, animal, material) in the R&D process, as a consequence. Quicker access to patients of safe and effective new medicines.

Three Regions, Six Parties Europe EUEFPIA Japan MHLWJPMA The United States of America FDAPhRMA

ICH Organisation The ICH Steering committee –ICH Coordinators –The ICH Secretariat (IFPMA) Expert Working Groups Administrative Technical

Steering Committee Meeting Attendees TWO MEMBERS FROM EACH OF THE SIX ICH PARTIES IFPMA (Secretariat) OBSERVERS from Canada, EFTA and WHO Oversees and monitors the Harmonisation Process.

Expert Working Groups SAFETY EFFICACY QUALITY REGULATORY COMMUNICATIONS An EWG for each ICH Topic Six Topic Leaders - one from each ICH party Role: developing consensus on technical issues

I C H INTERNATIONAL CONFERENCE ON HARMONISATION GUIDELINES

The Five Steps in the ICH Process for Harmonization of Technical Issues STEP 5: Implementation in the three ICH regions (Federal Register Notice Post on CDER Website) STEP 4: Agreement on a harmonized ICH guideline; adopted by regulators STEP 3: Regulatory consultation in the three regions. Consolidation of the comments (Federal Register Notice / Post on CDER Website) STEP 2: Agreement by the Steering Committee to release the draft consensus text for wider consultation STEP 1: Building scientific consensus in joint regulatory/industry expert working groups

INTERNATIONAL CONFERENCE ON HARMONIZATION First Conference: Brussels 1991 Second Conference: Orlando 1993 Third Conference: Yokohama 1995 Fourth Conference: Brussels 1997 Fifth Conference: San Diego 2000 Sixth Conference: Osaka 2003